Welcome to our dedicated page for Gain Therapeutics SEC filings (Ticker: GANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gain Therapeutics, Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common stock and emerging growth company status. Recent Form 8-K disclosures cover financial results, business updates, Regulation FD materials, scientific presentations, and clinical or biomarker updates related to GT-02287 and Parkinson’s disease.
The company’s proxy materials describe annual meeting matters, director elections, board composition, executive compensation, equity awards and auditor ratification. Other filings record governance changes, including board membership updates, and identify the company’s registered common stock, Delaware incorporation and reporting framework.
Gain Therapeutics, Inc. is an early-stage biotechnology company focused on small molecule treatments for protein-misfolding diseases. For the six months ended June 30, 2026, it reported a net loss of $10.3 million, similar to the prior-year period, driven by $4.9 million in research and development expenses and $5.1 million in general and administrative expenses.
Cash and cash equivalents were $13.1 million as of June 30, 2026, down from $20.8 million at year-end 2025, with $9.4 million used in operating activities in the first half of 2026. Management concluded that this cash balance will not fund operations for at least 12 months from issuance of the financial statements and stated that substantial doubt exists about the company’s ability to continue as a going concern beyond the second quarter of 2027 without additional capital.
The company’s lead candidate, rexaceract (GT-02287) for Parkinson’s disease, completed two Phase 1 studies and has an ongoing Phase 1b trial. In June 2026, Gain received FDA Investigational New Drug authorization to begin a Phase 2 study in Parkinson’s disease, anticipated to start in the third quarter of 2026 across sites in the United States, Australia and Europe. To support operations, Gain continues to access its at-the-market equity program and research grants, while also reviewing its cost structure and exploring strategic collaborations.
Gain Therapeutics reported second quarter 2026 results and provided an update on its Parkinson’s disease program. The company highlighted FDA authorization of its IND for rexaceract, supporting advancement into planned Phase 2 development, and ongoing enrollment and follow-up in a Phase 1b trial, including a nine‑month extension with data expected in October 2026.
For the quarter ended June 30, 2026, research and development expenses were $2.1 million, down from $2.8 million a year earlier, mainly due to lower costs for rexaceract and pipeline optimization, partially offset by the expiration of Swiss grant funding and foreign exchange effects. General and administrative expenses were $2.5 million, up from $2.3 million, driven by higher professional fees, personnel costs and currency impacts. Net loss was $4.7 million, or $0.11 per share, compared with $5.8 million, or $0.19 per share, in the prior‑year quarter.
As of June 30, 2026, cash and cash equivalents were $13.1 million, down from $20.8 million as of December 31, 2025. Total assets were $15.4 million and stockholders’ equity was $11.3 million. Gain continues to position rexaceract, a brain‑penetrant allosteric modulator of beta‑glucocerebrosidase, as a potential disease‑modifying therapy for Parkinson’s disease and other indications.
Gain Therapeutics, Inc. granted director GOLDSTEIN DOV A MD a stock option covering 25,000 shares of common stock at an exercise price of $1.68 per share. The option vests in 12 equal monthly installments beginning July 24, 2026, subject to his continuous service, and expires on July 15, 2036. Following this grant, he holds options on 25,000 shares.
Gain Therapeutics director Claude Nicaise received a grant of stock options covering 25,000 shares of common stock at an exercise price of $1.68 per share. The options expire on July 15, 2036 and vest in 12 equal monthly installments starting July 24, 2026, subject to his continuous service, resulting in 25,000 options held directly after the grant.
Gain Therapeutics director Khalid Islam reported a grant of stock options for 25,000 shares of common stock on July 15, 2026. The options carry a $1.6800 exercise price, expire on July 15, 2036, and vest in 12 equal monthly installments starting July 24, 2026, contingent on his continuous service.
Gain Therapeutics, Inc. reported that director Gwen A. Melincoff received a grant of stock options covering 25,000 shares of Common Stock on 2026-07-15. The options have an exercise price of $1.68 per share, expire on 2036-07-15, and result in direct ownership of 25,000 derivative securities.
According to the grant terms, the option vests in 12 equal monthly installments starting on July 24, 2026, subject to Melincoff’s continuous service through each applicable vesting date.
Gain Therapeutics director Jeffrey Scott Riley received a grant of stock options for 25,000 shares of common stock on July 15, 2026. The options have a $1.68 exercise price and expire on July 15, 2036. They vest in 12 equal monthly installments starting July 24, 2026, contingent on his continuous service, resulting in 25,000 options held directly after the grant.
Gain Therapeutics, Inc. reported that director Hans Peter Hasler received a grant of 25,000 stock options on 2026-07-15. The options have an exercise price of $1.68 per share for Gain Therapeutics common stock and expire on 2036-07-15. They vest in 12 equal monthly installments commencing on July 24, 2026, conditioned on his continuous service through each vesting date. Following this award, he directly holds 25,000 derivative securities linked to common stock. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.
Gain Therapeutics, Inc. reported, in a press release and shareholder letter, that its current cash and cash equivalents are anticipated to fund operations into the second quarter of 2027, based on current operating plans. This expected runway is tied to planned development activities.
The company highlighted plans to complete a Phase 1b open-label extension in October 2026 and to initiate a Phase 2 clinical study during the third quarter of 2026. Management described these as forward-looking statements and cautioned that actual results may differ materially.
Gain Therapeutics, Inc. reported that the U.S. Food and Drug Administration has authorized its Investigational New Drug application for GT-02287. This authorization allows the company to begin Phase 2 clinical development of GT-02287 in Parkinson’s disease, with or without a GBA1 mutation, in the United States.
Phase 1a and Phase 1b studies were conducted in Australia, and those sites are expected to participate in Phase 2 together with new sites in the U.S. and selected European centers. The company anticipates initiating the Phase 2/2a study of oral GT-02287 in treated and untreated participants with early Parkinson’s disease during the third quarter of 2026.